ROCHE’S plans to cut its global workforce by 6% will help to cement its “strong fiscal position over the next six years”, according to Datamonitor analyst, John Bird. The cuts are aimed at making annual cost savings of around $2.4 billion, which have been spurred on by imminent patent expiries and a drop in Tamiflu demand. “Despite all this the company’s operating profit in 2009 was above average,” Bird said.
The above article was sent to subscribers in Pharmacy Daily's issue from 18 Nov 10
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 18 Nov 10
